Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection

References

• Millier A, Schmidt U, Angermeyer MC, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014;54:85–93. doi:10.1016/j.jpsychires.2014.03.02124795289
   PubMed Web of Science ®Google Scholar
• Kane KM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5):IN18031AH1C. doi:10.4088/JCP.IN18031AH1C
   PubMed Web of Science ®Google Scholar
• Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia. A randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–1224. doi:10.1001/jamapsychiatry.2020.207632667636
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. The American psychiatric association practice guideline for the treatment of patients with schizophrenia, third edition; 2021. Available from: https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890424841. Accessed June 30, 2021.
   Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24. doi:10.4088/JCP.15032su127732772
   PubMed Web of Science ®Google Scholar
• Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505–524.25733955
   PubMed Web of Science ®Google Scholar
• Heres S. Long-acting injectable antipsychotics: an underutilized treatment option. J Clin Psychiatry. 2014;75(11):1263–1265. doi:10.4088/JCP.14com0954125470087
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226. doi:10.1002/wps.2006024096780
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2–3):109–113. doi:10.1016/j.psychres.2009.05.00420185182
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693. doi:10.1001/jamapsychiatry.2017.132228593216
   PubMed Web of Science ®Google Scholar
• Iyer S, Banks N, Roy M-A, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013;58(5Suppl 1):23S–29S. doi:10.1177/088740341305805s0423945064
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Ross R, Legacy SN, et al. Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part I. Neuropsychiatr Dis Treat. 2018;14:1463–1474. doi:10.2147/NDT.S16739429922062
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603–619. doi:10.1093/schbul/sbx09029868849
   PubMed Web of Science ®Google Scholar
• Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1–3):393–399. doi:10.1016/j.schres.2015.08.01526431793
   PubMed Web of Science ®Google Scholar
• Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–829. doi:10.1001/jamapsychiatry.2015.027026107752
   PubMed Web of Science ®Google Scholar
• Bridges JFP, Slawik L, Schmeding S, et al. A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia. Health Expect. 2013;16(2):164–176. doi:10.1111/j.1369-7625.2011.00704.x21668795
   PubMed Web of Science ®Google Scholar
• Eiring Ø, Landmark BF, Aas E, et al. What matters to patients? A systematic review of preferences for medication-associated outcomes in mental disorders. BMJ Open. 2015;5(4):e007848. doi:10.1136/bmjopen-2015-007848
   PubMed Web of Science ®Google Scholar
• Levitan B, Markowitz M, Mohamed AF, et al. Patients’ preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv. 2015;66(7):719–726. doi:10.1176/appi.ps.20140018825772762
   PubMed Web of Science ®Google Scholar
• Bridges JFP, Beusterien K, Heres S, et al. Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling. Patient Prefer Adherence. 2018;12:63–70. doi:10.2147/PPA.S15287029379273
   PubMed Web of Science ®Google Scholar
• Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: disease-specific programmes – a means to understand. Curr Med Res Opin. 2008;24(11):3063–3072. doi:10.1185/0300799080245704018826746
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale. Applying a research tool in clinical practice. Psychiatry. 2007;4(7):28–37.
   PubMedGoogle Scholar
• Reilly Associates. WPAI scoring. Available from: http://www.reillyassociates.net/WPAI_Scoring.html. Accessed January 11, 2021.
   Google Scholar
• Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ. No. ADM 76-338). Rockville, MD: National Institute of Mental Health; 1976:218–222.
   Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353–365. doi:10.2165/00019053-199304050-0000610146874
   PubMed Web of Science ®Google Scholar
• Giordano G, Tomassini L, Cuomo I, et al. Aripiprazole long-acting injection during first episode schizophrenia – an exploratory analysis. Front Psychiatry. 2020;10:935. doi:10.3389/fpsyt.2019.0093531969843
   PubMed Web of Science ®Google Scholar
• Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treat. 2012;2012:407171.
   PubMedGoogle Scholar
• Peitl V, Stefanovic M, Orlovic I, et al. Long acting aripiprazole influences cognitive functions in recent onset schizophrenia. Psychopharmacology. 2021;238(6):1563–1573. doi:10.1007/s00213-021-05788-w33580813
   PubMed Web of Science ®Google Scholar
• Potkin S, Bera R, Zubek D, Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry. 2013;13:261. doi:10.1186/1471-244X-13-26124131801
   PubMed Web of Science ®Google Scholar
• Kane JM, Schooler NR, Marcy P, et al. Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry. 2019;80(3):18m12546. doi:10.4088/JCP.18m12546
   PubMed Web of Science ®Google Scholar